Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Respiratory Syncytial Virus (RSV) Infections Overview 10
Therapeutics Development 11
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 11
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 12
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 13
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 18
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 24
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 29
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 30
Johnson & Johnson 30
F. Hoffmann-La Roche Ltd. 31
GlaxoSmithKline plc 32
Bavarian Nordic A/S 33
MedImmune, LLC 34
Gilead Sciences, Inc. 35
GenVec, Inc. 36
Ablynx NV 37
Emergent BioSolutions Inc. 38
Takeda Pharmaceutical Company Limited 39
Symphogen A/S 40
Celltrion, Inc. 41
Novavax, Inc. 42
Crucell N.V. 43
DBV Technologies 44
Mymetics Corporation 45
Pevion Biotech AG 46
Alnylam Pharmaceuticals, Inc. 47
Panacea Biotec Limited 48
Mucosis B.V. 49
Aridis Pharmaceuticals LLC 50
TechnoVax, Inc. 51
Okairos AG 52
AlphaVax, Inc. 53
Kineta, Inc. 54
MSM Protein Technologies, Inc. 55
Romark Laboratories, L.C. 56
REPLICor Inc. 57
NanoBio Corporation 58
Immunovaccine, Inc. 59
iBio, Inc. 60
Sirnaomics, Inc. 61
Alios BioPharma, Inc. 62
Merus B.V. 63
AIMM Therapeutics B.V. 64
3-V Biosciences, Inc. 65
Artificial Cell Technologies, Inc. 66
MicroDose Therapeutx, Inc. 67
AmVac AG 68
SelectX Pharmaceuticals, Inc. 69
Spider Biotech S.r.l. 70
Spring Bank Pharmaceuticals, Inc. 71
Complix NV 72
Sealife PHARMA GMBH 73
bioXPRESS Therapeutics SA 74
Panmira Pharmaceuticals, LLC. 75
Agilvax, Inc. 76
Biota Pharmaceuticals, Inc. 77
Humabs BioMed SA 78
Mapp Biopharmaceutical, Inc. 79
Codagenix, Inc. 80
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Target 82
Assessment by Mechanism of Action 85
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 93
RI-002 - Drug Profile 93
asvasiran sodium - Drug Profile 95
MDT-637 - Drug Profile 97
RI-001 - Drug Profile 99
Respiratory Syncytial Virus Vaccine - Drug Profile 100
ALS-8176 - Drug Profile 102
GS-5806 - Drug Profile 103
TMC-353121 - Drug Profile 104
nitric oxide - Drug Profile 105
MEDI-559 - Drug Profile 106
ALX-0171 - Drug Profile 107
Respiratory Syncytial Virus Vaccine - Drug Profile 108
RSV-001 - Drug Profile 110
GSK-3003891A - Drug Profile 111
GSK-3003892A - Drug Profile 112
GSK-3003893A - Drug Profile 113
GSK-3003895A - Drug Profile 114
GSK-3003896A - Drug Profile 115
GSK-3003898A - Drug Profile 116
GSK-3003899A - Drug Profile 117
Sym-003 - Drug Profile 118
MVA-BN RSV - Drug Profile 119
Vaccine For RSV - Drug Profile 120
AR-201 - Drug Profile 122
REP-9 - Drug Profile 123
AM-679 - Drug Profile 124
RSV Vaccine - Drug Profile 125
PEV-4 - Drug Profile 126
TVX-004 - Drug Profile 127
Respiratory Syncytial Virus Vaccine - Drug Profile 128
Respiratory Syncytial Virus-Virus Like Particle Vaccine - Drug Profile 130
RSV Vaccine - Drug Profile 131
palivizumab biosimilar - Drug Profile 132
Subunit Vaccine For Respiratory Syncytial Virus Infections - Drug Profile 133
SLP-0904 - Drug Profile 134
Mucosal Respiratory Syncytial Virus Vaccine - Drug Profile 135
STP-902 - Drug Profile 136
Drug For Respiratory Syncytial Virus Infections - Drug Profile 137
RSV Vaccine - Drug Profile 138
SynGEM - Drug Profile 139
RSV Vaccine - Drug Profile 140
Innate Immune Agonists - Drug Profile 141
rOAS - Drug Profile 142
AMV-603 - Drug Profile 143
AMV-611 - Drug Profile 144
ALS-8112 - Drug Profile 145
AMV-601 - Drug Profile 146
AMV-602 - Drug Profile 148
Antibody For Respiratory Syncytial Virus - Drug Profile 149
SB-105 - Drug Profile 150
Subunit Vaccine for Respiratory Syncytial Virus - Drug Profile 151
Monoclonal Antibodies for Respiratory Syncytial Virus Infections - Drug Profile 152
Anti-Viral Program - Drug Profile 153
palivizumab biosimilar - Drug Profile 154
SB105-A10 - Drug Profile 155
Respiratory Syncytial Virus Vaccine - Drug Profile 157
Drug For Respiratory Syncytial Virus Infections - Drug Profile 158
Monoclonal Antibody For Respiratory Syncytial Virus - Drug Profile 159
Liposomal siRNAs - Drug Profile 160
Respiratory Syncytial Virus Vaccine - Drug Profile 161
Vaccine to Inhibit Glycoprotein for RSV Infection - Drug Profile 162
Hemagglutinin-Fusion Protein Subunit Vaccine - Drug Profile 163
Fatty Acid Synthase Inhibitors Program For Virology - Drug Profile 164
Recombinant Granulocyte Macrophage Colony Stimulating Factor - Drug Profile 165
TVX-004IP - Drug Profile 166
MSM-605 - Drug Profile 167
Bispecific Antibodies For RSV - Drug Profile 168
RSV Fusion Inhibitors - Drug Profile 169
RSV Conjugates - Drug Profile 170
palivizumab biosimilar - Drug Profile 171
MVA-RSV - Drug Profile 173
Respiratory Syncytial Virus Vaccine - Drug Profile 174
palivizumab biosimilar - Drug Profile 175
SLP-1001 - Drug Profile 176
New Thiazolides - Drug Profile 177
Alphabody Program - Drug Profile 178
RSV-NanoViaSkin - Drug Profile 179
Monoclonal Antibody to Inhibit RSV-G and F Proteins for RSV Infection - Drug Profile 180
MAb Against RSV And MPV - Drug Profile 181
Drugs to Inhibit STAT for RSV Infection - Drug Profile 182
Live Attenuated Respiratory Syncytial Virus Vaccine - Drug Profile 183
Vaccines for Respiratory Syncytial Virus Infection - Drug Profile 184
asvasiran sodium - Drug Profile 185
Respiratory Syncytial Virus Vaccine - Drug Profile 187
Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 188
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 200
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 201
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 202
Featured News & Press Releases 202
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2014 17
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 20
Number of Products under Development by Companies, H1 2014 (Contd..1) 21
Number of Products under Development by Companies, H1 2014 (Contd..2) 22
Number of Products under Development by Companies, H1 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Comparative Analysis by Late Stage Development, H1 2014 26
Comparative Analysis by Clinical Stage Development, H1 2014 27
Comparative Analysis by Early Stage Development, H1 2014 28
Comparative Analysis by Unknown Stage Development, H1 2014 29
Products under Development by Companies, H1 2014 30
Products under Development by Companies, H1 2014 (Contd..1) 31
Products under Development by Companies, H1 2014 (Contd..2) 32
Products under Development by Companies, H1 2014 (Contd..3) 33
Products under Development by Companies, H1 2014 (Contd..4) 34
Products under Investigation by Universities/Institutes, H1 2014 35
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2014 36
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 37
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline plc, H1 2014 38
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2014 39
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H1 2014 40
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H1 2014 41
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H1 2014 42
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2014 43
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H1 2014 44
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 45
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Symphogen A/S, H1 2014 46
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H1 2014 47
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H1 2014 48
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Crucell N.V., H1 2014 49
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies, H1 2014 50
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corporation, H1 2014 51
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pevion Biotech AG, H1 2014 52
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 53
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2014 54
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H1 2014 55
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2014 56
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2014 57
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Okairos AG, H1 2014 58
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlphaVax, Inc., H1 2014 59
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H1 2014 60
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MSM Protein Technologies, Inc., H1 2014 61
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2014 62
Respiratory Syncytial Virus (RSV) Infections - Pipeline by REPLICor Inc., H1 2014 63
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H1 2014 64
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H1 2014 65
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H1 2014 66
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2014 67
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Alios BioPharma, Inc., H1 2014 68
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merus B.V., H1 2014 69
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AIMM Therapeutics B.V., H1 2014 70
Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences, Inc., H1 2014 71
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2014 72
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MicroDose Therapeutx, Inc., H1 2014 73
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AmVac AG, H1 2014 74
Respiratory Syncytial Virus (RSV) Infections - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 75
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech S.r.l., H1 2014 76
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014 77
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Complix NV, H1 2014 78
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sealife PHARMA GMBH, H1 2014 79
Respiratory Syncytial Virus (RSV) Infections - Pipeline by bioXPRESS Therapeutics SA, H1 2014 80
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panmira Pharmaceuticals, LLC., H1 2014 81
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2014 82
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2014 83
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2014 84
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mapp Biopharmaceutical, Inc., H1 2014 85
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H1 2014 86
Assessment by Monotherapy Products, H1 2014 87
Number of Products by Stage and Target, H1 2014 90
Number of Products by Stage and Mechanism of Action, H1 2014 93
Number of Products by Stage and Route of Administration, H1 2014 95
Number of Products by Stage and Molecule Type, H1 2014 98
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2014 194
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2014 206
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2014 207

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2014 17
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 19
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 27
Comparative Analysis by Early Stage Products, H1 2014 28
Assessment by Monotherapy Products, H1 2014 87
Number of Products by Top 10 Target, H1 2014 88
Number of Products by Stage and Top 10 Target, H1 2014 89
Number of Products by Top 10 Mechanism of Action, H1 2014 91
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 92
Number of Products by Top 10 Route of Administration, H1 2014 94
Number of Products by Stage and Top 10 Route of Administration, H1 2014 95
Number of Products by Top 10 Molecule Type, H1 2014 96
Number of Products by Stage and Top 10 Molecule Type, H1 2014 97
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.

Looking for something else?